Summaries of health policy coverage from major news organizations
GlaxoSmithKline to Begin Human Trials of AIDS Vaccine This Year
GlaxoSmithKline, the world's largest supplier of AIDS drugs, has announced plans to begin phase I clinical trials of a "novel" AIDS vaccine in the fourth quarter of this financial year, the Wall Street Journal reports. The vaccine showed "promising results" in lab tests on monkeys, which were protected from infection for more than a year after being injected. GSK, which commands 40% of the global AIDS drugs market, plans to test the drug as a prophylactic, or "preventive drug," later this year and expects to begin trials of the vaccine as a "therapeutic drug" next year. The company said that the vaccine could possibly be combined with a "cocktail" of drugs that it currently manufactures (Wall Street Journal, 2/23).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.